Eyenovia has closed its initial public offering of 2.73 million shares of its common stock, according to a press release.
Gross proceeds from the offering, before underwriting discounts and commissions, were $27.3 million. The company has granted underwriters a 30-day option to purchase up to 409,500 additional shares.
Eyenovia is developing ophthalmology products with its piezo-print technology to topically deliver microtherapeutics to the eye.
Ladenburg Thalmann & Co., a subsidiary of Ladenburg Thalmann Financial Services, and Roth Capital partners were joint book-running managers for the offering, the release said.